Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 13 ) 2008 NTT
|
|
|
- へいぞう あんさい
- 4 years ago
- Views:
Transcription
1 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 13 ) 2008 NTT
2 106 ( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr JA (80.5%) Enterococcus faecalis Enterococcus faecium Enterococcus avium Enterococcus spp. Streptococcus anginosus Streptococcus spp. Staphylococcus aureus
3 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 15 ) Staphylococcus spp. Enterococcus spp. Staphylococcus spp. Escherichia coli Klebsiella pneumoniae Pseudomonas aeruginosa P. aeruginosa E. coli Enterobacter cloacae K. pneumoniae Eggerthella lenta Parvimonas micra Streptococcus constellatus Gemella morbillorum E. lenta P. micra Bacteroides fragilis Bacteroides thetaiotaomicron Bacteroides ovatus Bilophila wadsworthia B. fragilis B. thetaiotaomicron B. wadsworthia B. ovatus (MRSA) Enterococcus spp I BTB 37 C 1 3 HK BBE PEA HK PV HK 37 C 3 7 MIC2000 Oxacillin (MPIPC) Ampicillin (ABPC) Tazobactam/Piperacillin (TAZ/PIPC) Cefazolin (CEZ) Cefotiam (CTM) Cefmetazole (CMZ)
4 108 ( 16 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Flomoxef (FMOX) Cefmenoxime (CMX) Latamoxef (LMOX) Ceftazidime (CAZ) Cefpirome (CPR) Cefepime (CFPM) Cefozopran (CZOP) Sulbactam/Cefoperazone (SBT/CPZ) Cefsulodin (CFS) Aztreonam (AZT) Carumonam (CRMN) Imipenem (IPM) Meropenem (MEPM) Gentamicin (GM) Amikacin (AMK) Arbekacin (ABK) Isepamicin (ISP) Clindamycin (CLDM) Minocycline (MINO) Ciprofloxacin (CPFX) Levofloxacin (LVFX) Linezolid (LZD) Vancomycin (VCM) Teicoplanin (TEIC) Fosfomycin (FOM) II (80.5%) Fig Table (68.8%) (60.0%) (68.9%) (92.5%) (95.5%) Fig. 1.
5 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 17 ) Table 1. Fig (57.2%) 38 (22.0%) 17 (9.8%) (Fig. 2) % 16.8% % 3 9.2% 4 7.5% % % % (Fig. 3)
6 110 ( 18 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Fig. 3. Table Table (Candida albicans 5 Candida glabrata 2 Candida kefyr Zygosaccharomyces fermentati 1 9 C. albicans 8 C. glabrata (Table 3)
7 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 19 ) Table 3.
8 112 ( 20 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Enterococcus faecalis Streptococcus anginosus Enterococcus faecium Enterococcus avium Staphylococcus aureus E. faecalis S. aureus Staphylococcus epidermidis E. faecium E. avium Enterococcus spp. Streptococcus spp. Enterococcus spp. Staphylococcus spp (Table 4) Eggerthella lenta Parvimonas micra Streptococcus constellatus Gemella morbillorum E. lenta P. micra Finegoldia magna (Table 5) Escherichia coli Klebsiella pneumoniae Pseudomonas aeruginosa Klebsiella oxytoca P. aeruginosa E. coli Enterobacter cloacae K. pneumoniae (Table 6) Bacteroides fragilis Bacteroides thetaiotaomicron Bacteroides ovatus Bilophila wadsworthia B. fragilis B. thetaiotaomicron B. wadsworthia B. ovatus Bacteroides spp. E. coli Enterococcus spp. Staphylococcus spp. P. aeruginosa (Fig. 4) 3 (Fig. 5) E. coli B. fragilis 2 (Fig. 6) (Fig. 7)
9 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 21 ) Table 4.
10 114 ( 22 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Table 5.
11 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 23 ) Table 6.
12 116 ( 24 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Fig. 4. Fig. 5. 1
13 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 25 ) Fig Fig. 7. 1
14 118 ( 26 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr E. faecalis S. aureus % P. aeruginosa % % E. coli 10% (Fig. 8) MRSA S. aureus MRSA % (Fig. 9) Bacteroides spp. (18.9%) (23.3%) E. coli (9.9%) Enterococcus spp. (6.0%) Streptococcus spp. (5.9%) E. coli 1990 (Fig. 10) 5 Enterococcus spp. (18.5%) Bacteroides spp. (15.0%) (12.7%) (12.0%) Staphylococcus spp. (10.1%) 1999 Staphylococcus spp. Fig. 8. 2
15 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 27 ) Fig. 9. MRSA Fig. 10.
16 120 ( 28 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Fig. 11. (Fig. 11) E. coli Klebsiella spp Enterococcus spp. E. coli Klebsiella spp. 5 Klebsiella spp. (Fig. 12) 1994 Enterococcus spp. 5 Enterobacter spp. (16.1%) Klebsiella spp. (9.7%) P. aeruginosa (9.7%) E. coli (9.7%) (Fig. 13) 3 5 Bacteroides spp. 40.8% Enterococcus spp. Staphylococcus spp. E. coli Klebsiella spp. (Fig. 14) 5 Table 7 44 MIC 1 Staphylococcus spp. S. aureus 24 MPIPC MIC mg/ml 19 (79.2%)
17 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 29 ) Fig. 12. Fig. 13.
18 122 ( 30 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Fig mg/ml ABPC 5 MIC 0.5 mg/ml 1 4 mg/ml mg/ml VCM TEIC LZD MIC 2 mg/ml ABK 1 MIC 8 mg/ml MIC 2 mg/ml GM 9 MIC 1 mg/ml MIC 8 mg/ml CLDM 6 MIC mg/ml 18 MIC 128 mg/ml (Table 7) S. epidermidis 22 MPIPC MIC 1 MIC mg/ml 1 mg/ml 20 4 mg/ml MINO MIC 0.25 mg/ml MIC 90 LZD ABK VCM TEIC LVFX CZOP CTM CLDM MIC mg/ml mg/ml 8 (Table 8) Staphylococcus spp. 7 (Staphylococcus capitis 3 Staphylococcus caprae 2 Staphylococcus haemolyticus Staphylococcus lugdunensis 1 MIC 90 MINO ABK TEIC LZD VCM LVFX (Table 9) 2 Streptococcus spp. S. anginosus 13 CMX MIC mg/ml MEPM IPM CPR TEIC ABPC TAZ/PIPC MIC 0.25 m g/ml CLDM 2 MIC 128 mg/ml 0.25 mg/ml FOM (Table 10)
19 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 31 ) Table 7. Staphylococcus aureus 24
20 124 ( 32 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Table 8. Staphylococcus epidermidis 22
21 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 33 ) Table 9. Staphylococcus spp. 7
22 126 ( 34 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Table 10. Streptococcus anginosus 13
23 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 35 ) Table 11. Streptococcus spp. 12
24 128 ( 36 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Table 12. Enterococcus faecalis 46
25 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 37 ) Table 13. Enterococcus faecium 15
26 130 ( 38 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Table 14. Enterococcus avium 12
27 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 39 ) Table 15. Enterococcus spp. 13
28 132 ( 40 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Table 16. Corynebacterium spp. 11
29 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 41 ) Table 17. Escherichia coli 51
30 134 ( 42 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Table 18. Klebsiella pneumoniae 19
31 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 43 ) Table 19. Klebsiella oxytoca 8
32 136 ( 44 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Table 20. Enterobacter cloacae 13
33 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 45 ) Table 21. Citrobacter spp. 11
34 138 ( 46 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Table 22. Pseudomonas aeruginosa 23
35 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 47 ) Table 23. Streptococcus constellatus 12
36 140 ( 48 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Table 24. Gemella morbillorum 10
37 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 49 ) Table 25. Finegoldia magna 7
38 142 ( 50 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Table 26. Parvimonas micra 18
39 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 51 ) Table 27. Eggerthella lenta 22
40 144 ( 52 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Table 28. Lactobacillus spp. 14
41 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 53 ) Table 29. Bifidobacterium spp. 5
42 146 ( 54 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Table 30. Propionibacterium spp. 8
43 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 55 ) Table 31. Clostridium spp. 19
44 148 ( 56 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Table 32. Bacteroides fragilis 37
45 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 57 ) Table 33. Bacteroides thetaiotaomicron 27
46 150 ( 58 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Table 34. Bacteroides ovatus 19
47 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 59 ) Table 35. Bacteroides uniformis 10
48 152 ( 60 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Table 36. Bacteroides spp. 116
49 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 61 ) Table 37. Bilophila wadsworthia 19
50 154 ( 62 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Table 38. Veillonella spp. 8
51 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 63 ) Table 39. Fusobacterium nucleatum 12
52 156 ( 64 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Table 40. Fusobacterium spp. 10
53 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 65 ) Table 41. Prevotella intermedia 10
54 158 ( 66 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Table 42. Prevotella spp. 17
55 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 67 ) Table 43. Porphyromonas spp. 9
56 160 ( 68 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Table 44. Parabacteroides distasonis 11
57 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 69 ) Streptococcus spp. 12 Streptococcus salivarius 3 Streptococcus oralis Streptococcus mitis 2 Streptococcus sanguis Streptococcus parasanguinis Streptococcus bovis 1 Streptococcus spp. 2 TEIC MIC 0.25 m g/ml CMX CPR IPM MEPM CFPM CZOP VCM LZD (Table 11) 3 Enterococcus spp. E. faecalis 46 TEIC MIC 0.5 mg/ml ABPC LZD VCM IPM TAZ/PIPC (Table 12) E. faecium 15 TEIC MIC 0.5 mg/ml VCM MIC 1 mg/ml LZD MIC 2 mg/ml MINO MIC 8 mg/ml (Table 13) E. avium 12 TEIC MIC 0.5 mg/ml VCM LZD CPFX LVFX MINO (Table 14) Enterococcus spp. 13 Enterococcus pseudoavium 3 Enterococcus gallinarum Enterococcus raffinosus 2 Enterococcus hirae Enterococcus mundtii 1 Enterococcus spp. 4 TEIC LZD VCM MINO LVFX CPFX (Table 15) 4 Corynebacterium spp. Corynebacterium spp. 11 Corynebacterium striatum 5 Corynebacterium minutissimum Corynebacterium argentoratense 1 Corynebacterium spp. 4 LZD TEIC VCM MINO (Table 16) 5 Escherichia coli E. coli 51 MIC 90 MEPM MIC m g/ml CFPM CPR CZOP CMX FMOX CRMN 0.25 mg/ml IPM AZT LMOX MIC 128 mg/ml ABPC 12 CEZ CTM CMX CPR CZOP TAZ/PIPC 2 (Table 17 6 Klebsiella spp. K. pneumoniae 19 ABPC FOM (Table 18) K. oxytoca 8 K. pneumoniae CEZ (Table 19) 7 Enterobacter cloacae E. cloacae 13 FOM FMOX MIC 90 MEPM mg/ml CPFX LVFX GM IPM CFPM AMK MINO CZOP CPR (Table 20) 8 Citrobacter spp. Citrobacter spp. 11 Citrobacter freundii 6 Citrobacter koseri Citrobacter amalonaticus
58 162 ( 70 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Citrobacter braakii 1 MEPM CFPM CPR CZOP CRMN CPFX LMOX (Table 21) 9 Pseudomonas aeruginosa P. aeruginosa 23 MIC 90 CPFX CZOP LVFX 2 mg/ml GM CAZ 4 mg/ml (Table 22) IPM MIC 16 mg/ml 5 (21.7%) AMK CPFX CPFX MIC 4 mg/ml 1 (4.3%) IPM AMK AMK MIC 32 mg/ml 3 MIC 64 mg/ml CZOP MIC 4 mg/ml 10 Streptococcus constellatus S. constellatus 12 IPM CLDM MEPM TEIC CMX CPR MIC 0.25 mg/ml (Table 23) 11 Gemella morbillorum G. morbillorum 10 FOM CAZ (Table 24) 12 Finegoldia magna F. magna 7 TAZ/PIPC TEIC MEPM ABPC FMOX VCM IPM (Table 25) 13 Parvimonas micra P. micra 18 CLDM (Table 26) 14 Eggerthella lenta E. lenta 22 TEIC MIC 0.25 mg/ml LZD MEPM ABPC VCM IPM (Table 27) 15 Lactobacillus spp. Lactobacillus spp. 14 (Lactobacillus acidophilus 5 Lactobacillus casei 4 Lactobacillus gasseri 3 Lactobacillus fermentum Lactobacillus sp. 1 MIC 90 ABPC MIC 2 mg/ml TAZ/PIPC LZD MINO IPM (Table 28) 16 Bifidobacterium spp. Bifidobacterium spp. 5 MINO TEIC ABPC IPM MEPM LZD VCM (Table 29) 17 Propionibacterium spp. Propionibacterium spp. 8 Propionibacterium acnes 4 Propionibacterium granulosum 2 Propionibacterium thoenii Propionibacterium sp. 1 IPM ABPC MINO TAZ/PIPC MEPM CMX (Table 30) 18 Clostridium spp. Clostridium spp. 19 Clostridium clostridioforme 6 Clostridium perfringens 3 Clostridium difficile Clostridium symbiosum 2
59 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 71 ) Clostridium bifermentans Clostridium paraputrificum 1 Clostridium spp. 4 TEIC MEPM LZD MIC 2 mg/ml VCM FMOX 4 mg/ml ABPC CTM CFPM CZOP CLDM LVFX FOM (Table 31) 19 Bacteroides spp. B. fragilis 37 MIC 90 TAZ/PIPC 0.5 m g/ml 1 mg/ml IPM 2 mg/ml MEPM 4 mg/ml MINO SBT/CPZ (Table 32) CPR CFPM CZOP CLDM B. thetaiotaomicron 27 MIC 90 IPM 1 mg/ml 2 mg/ml MEPM 4 mg/ml MINO 8 mg/ml TAZ/ PIPC SBT/CPZ (Table 33) CPR CFPM CZOP CLDM B. ovatus 19 MIC 90 MEPM 1 mg/ml 2 mg/ml IPM MINO 4 mg/ml TAZ/PIPC 8 mg/ml SBT/CPZ (Table 34) CPR CFPM CZOP CLDM Bacteroides uniformis 10 MIC 90 MEPM IPM 0.5 mg/ml 2 mg/ml MINO TAZ/PIPC 8 mg/ml SBT/CPZ (Table 35) CPR CFPM CZOP CLDM B. fragilis 37 B. thetaiotaomicron 27 B. ovatus 19 B. uniformis 10 Bacteroides vulgatus 8 Bacteroides caccae 8 Bacteroides splanchnicus 1 Bacteroides spp MIC 90 MEPM IPM 1 mg/ml 4 mg/ml MINO 8 mg/ml TAZ/PIPC SBT/CPZ (Table 36) CLDM MIC 50 1 mg/ml 44 (37.9%) MIC 128 mg/ml CFPM CZOP CPR 20 Bilophila wadsworthia B. wadsworthia 19 MIC 90 MINO 2 mg/ml MIC 2 mg/ml CPFX LVFX CLDM MIC mg/ml 2 (Table 37) 21 Veillonella spp. Veillonella spp. 8 TEIC VCM CAZ CLDM MIC 0.25 mg/ml (Table 38) 22 Fusobacterium spp. Fusobacterium nucleatum 12 TAZ/PIPC MEPM MINO CLDM FMOX IPM CLDM 1 (Table 39) Fusobacterium spp. 10 Fusobacterium varium 5 Fusobacterium necrophorum 3 Fusobacterium spp. 2 MEPM
60 164 ( 72 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr MIC 0.5 mg/ml MINO CMX FMOX IPM TAZ/PIPC Table Prevotella spp. Prevotella intermedia 10 TAZ/PIPC IPM MEPM SBT/CPZ LVFX CPFX MINO (Table 41) Prevotella spp. 17 (Prevotella melaninogenica 5 Prevotella oris 3 Prevotella denticola Prevotella corporis 2 Prevotella buccae Prevotella loescheii Prevotella bivia 1 Prevotella spp. 2 TAZ/PIPC MEPM IPM SBT/CPZ MINO (Table 42) 24 Porphyromonas spp. Porphyromonas spp. 9 Porphyromonas asaccharolytica 5 Porphyromonas gingivalis 1 Porphyromonas endodontalis 3 (Table 43) 25 Parabacteroides distasonis P. distasonis 11 IPM MEPM MINO (Table 44) III. phylotype 32,33) (Domain Bacteria) (Domain Archaea) 1 34) 35 38) S. aureus MRSA 80% VCM ABK TEIC LZD (CNS) CNS VCM ABK TEIC LZD MRSA MRSA MRSA MRSA b- G MRSA
61 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 73 ) E. coli 1990 CEZ 100 mg/ml MIC 10% 11,13 15) ) ) CEZ CEZ MIC 128 mg/ml 2 Extended spectrum b-lactamases (ESBLs) P. aeruginosa IPM MIC 16 mg/ml 5 (21.7%) AMK CPFX IPM D2 b- 39) IPM MIC 16 mg/ml 32 mg/ml IPM CPFX MIC 4 mg/ml 1 (4.3%) IPM AMK CPFX DNA AMK b- AMK MIC 32 mg/ml 3 IPM IPM CZOP Lactobacillus spp. Clostridium spp. Bacteroides spp. B. wadsworthia 40,41) E. lenta B. fragilis Bacteroides spp. B. wadsworthia C. gracilis Prevotella spp. MINO 2 CLDM MINO VCM ESBLs E. coli P. aeruginosa Bacteroides
62 166 ( 74 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr spp. B. wadsworthia Prevotella spp. b 1) 1 Jpn. J. Antibiotics 39: , ) 2 Jpn. J. Antibiotics 41: , ) 37: , ) (MRSA) 2: , ) 3: , ) 4: 43 49, ) MRSA 5: , ) Jpn. J. Antibiotics 47: , ) Jpn. J. Antibiotics 47: , ) 24: 40 45, ) Escherichia coli Jpn. J. Antibiotics 49: , ) Pseudomonas aeruginosa Jpn. J. Antibiotics 49: , ) 1994 Jpn. J. Antibiotics 49: , ) 1995 Jpn. J. Antibiotics 50: , ) 1996 Jpn. J. Antibiotics 52: , ) Bacteroides fragilis group 28: 48 54, ) 29: , ) 30: 36 43, ) 30: , ) 1997 Jpn. J. Antibiotics 53: , ) 1998 Jpn. J. Antibiotics 54: , ) 32: , 2002
63 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 75 ) 23) 1999 Jpn. J. Antibiotics 55: , ) 2000 Jpn. J. Antibiotics 55: , ) 2001 Jpn. J. Antibiotics 56: , ) 2002 Jpn. J. Antibiotics 57: 33 69, ) 2003 Jpn. J. Antibiotics 58: , ) 2004 Jpn. J. Antibiotics 59: , ) 2005 Jpn. J. Antibiotics 60: 52 97, ) 2006 Jpn. J. Antibiotics 61: , ) 2007 Jpn. J. Antibiotics 62: , ) HEBB, J. K.; C. R. COHEN, S. G. ASTETE, et al.: Detection of novel organisms associated with salpingitis, by use of 16S rdna polymerase chain reaction. J. Infect. Dis. 190: , ) SIQUEIRA, J. F.; I. N. ROCAS, C. D. CUHA, et al.: Novel bacterial phylotypes in endodontic infections. J. Dent. Res. 84: , ) Jpn. J. Antibiotics 60: , ) 62: , ) 3: , ) SIRS PMX-DHP 3: , ) 8: 26 30, ) MDRP 34: 83 86, ) Clostridium spp. Jpn. J. Antibiotics 60: , ) Bilophila wadsworthia Jpn. J. Antibiotics 59: , 2006
64 168 ( 76 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Bacteria isolated from surgical infections and its susceptibilities to antimicrobial agents Special references to bacteria isolated between April 2008 and March 2009 NAGAO SHINAGAWA and MASAMITSU HASEGAWA Department of Surgery, NTT West Tokai Hospital KOICHI HIRATA, TOMOHISA FURUHATA and TOHRU MIZUKUCHI First Department of Surgery, Sapporo Medical University, School of Medicine HIROYUKI OSANAI Department of Surgery, Sapporo Gekakinen Hospital YOSHIYUKI YANAI Department of Surgery, Medical Corporation Teishinkai Shinsapporokeiaikai Hospital FUMITAKA HATA Department of Surgery, Sapporo Doto Hospital KAZUAKI SASAKI, TETSUFUMI SOMEYA, KEISUKE HARADA and KEISUKE OONO Department of Surgery, Otaru Ekisaikai Hospital SHOJI TOKITA and MASASHI NAKAMURA Department of Surgery, Noboribetsu Kosei-Nenkin Hospital HITOSHI SHIBUYA Department of Surgery, Muroran City General Hospital ITARU HASEGAWA, MASAMI KIMURA, HIDEKI OSHIMA and HIDEKI MAEDA Department of Surgery, Hokkaido Saiseikai Otaru Hospital MITSUHIRO MUKAIYA and CHIKASI KIHARA Department of Surgery, Hokkaidou Social Service Association Hakodate Hospital WATABE KOSHO Department of Surgery, Akabira General Hospital TSUYOSHI HOSHIKAWA and HITOSHI KIMURA Department of Surgery, Takikawa Municipal Hospital YASUHIDE USHIJIMA and YOO YAE-HOON Department of Surgery, National Hospital Organization, Saitama National Hospital NAOKI AIKAWA and SHINYA ABE Department of Emergency and Critical Care Medicine, School of Medicine, Keio University JIRO YURA Digestive Disease Center, Matsunami General Hospital HIROMITSU TAKEYAMA and TAKEHIRO WAKASUGI Nagoya City University Graduate School of Medical Sciences, Department of Gastroenterological Surgery MASAAKI TANIGUCHI Department of Surgery, Ookuma Hospital ISAMU MIZUNO and TAKUJI FUKUI Department of Surgery, Nagoya Midori Municipal Hospital KEIJI MASHITA Department of Surgery, Bisai Hospital SYU ISHIKAWA Department of Surgery, Kariya Toyota General Hospital, Takahama Branch AKIRA MIZUNO Department of Surgery, Inabe General Hospital
65 Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 77 ) NORIAKI MOORI and NAOKI SUMITA Department of Surgery, Chita Kosei Hospital SHOJI KUBO and SHIGERU LEE Department of Gastroenterological and Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine TORU OOMURA Department of Surgery, Fujiidera City Hospital YASUHITO KOBAYASHI and TAKESHI TSUJI Department of Surgery, Wakayama Rosai Hospital HIROKI YAMAUE and MANABU KAWAI Second Department of Surgery, Wakayama Medical School YOSHIO TAKESUE Department of Infection Control, Hyogo Medical School NORIAKI TANAKA Dept. of Gastroenterological Surgery, Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences HIDEYUKI KIMURA Department of Surgery, Okayama Saiseikai Hospital HIROMI IWAGAKI Department of Surgery, National Hospital Organization, Fukuyama National Hospital TAIJIRO SUEDA, EISO HIYAMA, YOSHIAKI MURAKAMI, HIROKI OOGE and KENICHIRO UEMURA Department of Surgery, Graduate School of Biomedical Sciences, Hiroshima University HIROAKI TSUMURA Department of Surgery, Hiroshima City Funairi Hospital TAKASHI YOKOYAMA Aki City Hospital HITOSHI TAKEUCHI and KOUJI TANAKAYA Department of Surgery, National Hospital Organization, Iwakuni National Hospital YOICHI YASUNAMI and SHINICHIRO RYU Department of Surgery 1, Fukuoka University, School of Medicine Bacteria isolated from infections in abdominal surgery during the period from April 2008 to March 2009 were investigated in a multicenter study in Japan, and the following results were obtained. In this series, 712 strains including 18 strains of Candida spp. were isolated from 173 (80.5%) of 215 patients with surgical infections. Three hundred and sixty-six strains were isolated from primary infections, and 346 strains were isolated from postoperative infections. From primary infections, anaerobic Gram-negative bacteria were predominant, followed by aerobic Gram-negative bacteria, while from postoperative infections aerobic Gram-positive bacteria were predominant, followed by anaerobic Gram-negative bacteria. Among aerobic Gram-positive bacteria, the isolation rate of Enterococcus spp. was highest, followed by Streptococcus spp., and Staphylococcus spp. in this order, from primary infections, while Enterococcus spp. was highest, followed by Staphylococcus spp. from postoperative infections. Among aerobic Gram-negative bacteria, Escherichia coli was the most predominantly isolated from primary infections, followed by Klebsiella pneumoniae and Pseudomonas aeruginosa, in this order, and from postoperative infections, P. aeruginosa was most predominantly isolated, followed by E. coli, Enterobacter cloacae, and K. pneumoniae. Among anaerobic Gram-positive bacteria, the isolation rate of Eggerthella lenta was the highest from primary infections, followed by Parvimonas micra, Streptococcus constellatus and Gemella morbillorum, and from postoperative infections, E. lenta was most predominantly isolated.
66 170 ( 78 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr Among anaerobic Gram-negative bacteria, the isolation rate of Bacteroides fragilis was the highest from primary infections, followed by Bacteroides thetaiotaomicron, Bacteroides ovatus and Bilophila wadsworthia, and from postoperative infections, B. fragilis was most predominantly isolated, followed by B. thetaiotaomicron, B. wadsworthia and B. ovatus, in this order. In this series, we noticed no vancomycin-resistant methicillin-resistant S. aureus, and Enterococcus spp., nor multidrug-resistant P. aeruginosa. We should carefully follow up B. wadsworthia which was resistant to various antibiotics, and also Bacteroides spp. which was resistant to many b lactam antibiotics.
02-(a)-Łi’ì™·Łv-4.11
THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 105( 13 ) 2001 1) 2) 3) JA 2 7 1) 2) 3) 106( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. 1982 7 2001 (2001.4 2002.3) 1 221 175 (79.2%) 420 186 234 Staphylococcus
THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 33( 33 ) 2002 JA * 1 * 2 2003 12 15 * 1) * 2) 34( 34 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 1982 7 2002 (2002.4 2003.3) 1 174 131 (75.3%) 334 171 163 Staphylococcus
Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (9) 2007 NTT JA
Aug. 2009 THE JAPANESE JOURNAL OF ANTIBIOTICS 62 44 277 (9) 2007 NTT JA 278 (10) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug. 2009 2009 4 10 1982 7 2007 2007 4 2008 3 1 229 181 (79.0%) 683 24 395 288
Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis
Staphylococcus aureus S. aureus (MRSA) vancomycin (VCM), arbekacin (ABK) Streptococcus pneumoniae cefuzonam (CZON), cefpirome (CPR) S. pneumoniae Enterococcus faecalis ampicillin (ABPC), imipenem (IPM)
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis, E.coil,Klebsiella pneumoniae,klebsiella oxytoca,proteus
03-b-„FŒ{›xŒ¾-4.02
518( 30 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 1. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 519( 31 ) 9 5 2003 8 2004 7 14 565 701 258 (36.8%) 443 (63.2%) Staphylococcus aureus
R06_01
Staphylococcus aureus (MSSA) PCG (N=118,334) 57,369 (48.5%) 判定不能 :3 (0.0%) 60,962 (51.5%) CEZ (N=143,723) I:42 (0.0%) 143,635 (99.9%) R:46 (0.0%) CVA/AMPC (N=19,281) R:14 (0.1%) 19,265 (99.9%) 判定不能 :2
日本化学療法学会雑誌第64巻第4号
β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.
untitled
111-245010-N-04 21300AMY00327000 20116 2 20099 1 BD BBLCRYSTAL ANR BD BBLCRYSTAL ANR 4-A 2-A 1-A 4-B 2-B 1-B 4-C 2-C 1-C 4-D 2-D 1-D 4-E 2-E 1-E 4-F 2-F 1-F 4-G 2-G 1-G 4-H 2-H 1-H 4-I 2-I 1-I 4-J 2-J
日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
Dec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 45 ) ) 1) 2) 2) 3) 4) 4,5) 6) 6) 7) 8) 8) 9) 10) 11) 11) 12) 13) 13) 14) 14) 15) 15) 1
Dec. 2010 THE JAPANESE JOURNAL OF ANTIBIOTICS 63 46 431 ( 45 ) 2006 1) 1) 2) 2) 3) 4) 4,5) 6) 6) 7) 8) 8) 9) 10) 11) 11) 12) 13) 13) 14) 14) 15) 15) 16) 16) 17) 17) 1) 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10)
CHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
2.7 臨床概要
2.7 臨床概要 A/G Al-P ALT AST AT- AUC AZM BIPM BP BUN CEZ CFPN-PI CFU CLcr Cmax CNS COPD CPFX CRP CS CYP CVA DBT DHP-I DIC DRPM DRPM-DC FAS γ-gtp GCP GNB GNF-GNR GPB HAM - Staphylococcus C P450 -I Full Analysis
日本化学療法学会雑誌第51巻第4号
000 000 0 000 0 Methicillin resistant Staphylococcus aureusmrsa.methicillin resistant S. epidermidismrse.0 MRSA MRSE arbekacinabkquinupristindalfopristinqprdpr vancomycin MIC0. ml Streptococcus pneumoniae
70( 70 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Meropenem 2002 * * * * * * * * * * * * * * * * * * * * * * NTT Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 71( 71 ) * * * * 2003 12 22 Meropenem
R01
1. 集計対象医療機関数 (1,792 医療機関 ) 13.2% (7 医療機関 ) 900 床以上 N=53 86.8% (46 医療機関 ) 19.2% (70 医療機関 ) 500 899 床 N=365 80.8% (295 医療機関 ) JANIS 参加 * 200 499 床 N=2,231 43.4% (968 医療機関 ) 56.6% (1,263 医療機関 ) JANIS 参加 200
PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC= Piperacillin
Key words : Clinical isolates, Antibacterial susceptibility, Scale of hospital PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC=
CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella
THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium
THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterobacter spp., Serratia spp., Burkholderia cepacia, Flavobacterium spp., Alcaligenes spp. THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 Feb Neisseria gonorrhoeae ceftriaxone CTRX % 2010 CTRX 20 FQ staphylococci, E. faecium, N.
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 1 1 2013 69 11,762 2015 11 16 1994 2013 69 19 11,762 FQ 33 Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae
Table 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil
日本化学療法学会雑誌第53巻第S-3号
moxifloxacin in vitro moxifloxacin in vitro 17 9 6 17 11 21 moxifloxacinmflx in vitro cefdinir CFDNclavulanic acidamoxicillincvaampcclarithromycincamclindamycincldm levofloxacinlvfx 1MFLX Clostridium clostridiiformeclostridium
04-c-„FŒ{›xŒ¾-4.01
544( 56 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 2. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 545( 57 ) 9 5 2003 8 2004 714 565 719 50 20 39 0 9 70 79 44.4 91.7% Escherichia coli
Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 11( 11 ) 2003 12 17 (MRSA) penicillin-resistant Streptococcus pneumoniae (PRSP) 3 I. 12( 12 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 3 1997 1) (1985)
Oct THE JAPANESE JOURNAL OF ANTIBIOTICS Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, taz
Oct. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 5 327 27 2013 2014 2016 7 5 2013 2014 Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, tazobactam/piperacillin TAZ/PIPC, ceftazidime CAZ, cefepime
1.Streptococcus pneumoniae, Streptococcus pyogenes JC-1,S.aureus Smith,methicillin (DMPPC)- susceptible S. aureus subsp. aureus (MSSA) TR101, DMPPC-resistant S. aureus subsp. aureus (MRSA) TR102, Staphylococcus
VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus
MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,
VOL. 43 NO. 4
VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics
CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc
APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marcescens P. aeruginosa P. aeruginosa Streptococcus pyogenes Streptococcus
Table 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains
untitled
Seminal paper Anhalt JP Pioneering paper Claydon MA Kishnamurthy T Enterobacter B. cereus Routine identification paper Eigner U Seng P Cherkaoui A Saureus S. Saureus* S. Vagococcus Haemophilus Mycobacterium
CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle
VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
DIC vegetation 1 nonbacterial thrombogenic e
2001 2002 Guidelines for the Prevention and Treatment of Infective Endocarditis (JCS 2003) h 1 1 2 3 4 5 6 7 8 9 2 1 2 3 1 2 3 4 1 2 5 1 2 1 G Streptococcus viridans Streptococcus bovis 2 G Streptococcus
CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk
VOL. 30 S-3 CHEMOTHERAPY imeumoniae, Serratia marcescens, Proteus sp, CHEMOTHERAPY DEC. 1982 Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus,
Table 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against
公開情報 2016 年 1 月 ~12 月年報 ( 全集計対象医療機関 ) 院内感染対策サーベイランス検査部門 Citrobacter koseri Proteus mirabilis Proteus vulgaris Serratia marcescens Pseudomonas aerugino
公開情報 2016 年 1 月 ~12 月年報 ( 全集計対象医療機関 ) 院内感染対策サーベイランス検査部門 検査部門におけるサーベイランスの概要と目的 本サーベイランスの目的は 細菌検査により検出される主要な細菌の分離頻度とその抗菌薬感受性を継続的に収集 解析し 医療機関における主要な細菌ならびに薬剤耐性菌の分離状況を明らかにすることである サーベイランスの対象となる主要菌ならびに薬剤耐性菌の分離率は
Table 1. Antimicrobial drugs using for MIC
Table 1. Antimicrobial drugs using for MIC Table 2. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive eategory for Staphylococcus aureus Table 3. Interpretive
(ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor (CCL), Cephalothin (CET), Cefazolin (CEZ), Cefotia
Key words: Blood culture, Trend of bacterial isolation, Increasing of staphylococcus, Use of new cephems (ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor
Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia
ceftazidime, cefpirome, cefepime, cefoperazone/sulbactam (2: 1), imipenem Staphylococcus aureus oxacillin coagulase negative staphylococci Escherichia coli piperacillin Klebsiellac spp. Citrobacter Pseudomonas
ｽﾗｲﾄﾞ ﾀｲﾄﾙなし
第 4 回ひびき臨床微生物シンポジュウム June 24,27, 港ハウス 感受性検査を読む ( 同定検査結果確認やスクリーニング検査と捉えて ) ( 株 ) キューリン小林とも子 キューリン微生物検査課 塗抹鏡検グラム染色 分離培養検査血液 BTB, エッグーヨーク 報告書作成結果承認 同定検査 VITEK TSI,LIM クリスタル NF 薬剤感受性検査 MIC2 ディスク法 薬剤感受性結果 (
VOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
CHEMO THE RAPY OCT. 1994
bilis (0.78), Proteus vulgaris (1.56), Enterococcus faecalis (3.13), Staphylococcus epidermidis (6.25), Klebsiella pneumoniae (6.25), Morganella morganii (6.25), Escherichia coli (12.5), Providencia rettgeri
概要 (2004 年分 ) 本サーベイランスは 参加医療機関において血液および髄液から分離された各種細菌の検出状況や薬剤感受性パターンの動向を把握するとともに 新たな耐性菌の早期検出等を目的とする これらのデータを経時的に解析し臨床の現場に還元することによって 抗菌薬の安全で有効な使用方法や院内感染制御における具体的かつ確実な情報を提供する 検体 ( ) 内は施設数 2002 年 2003 年 2004
CHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum
VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae methicillin-resistant Staphylococcus
Key words: Antibiotics, Intestinal bacterial flora, Germfree mouse
Key words: Antibiotics, Intestinal bacterial flora, Germfree mouse Table 1 Susceptibility to various antibiotics Antibiotics Abbreviations ABPC: GM: CET: CEZ: CMZ: LMOX: CMX: Bacteriae used Ampicillin
VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St
CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table
Microsoft PowerPoint ．片山（HP用修正）.pptx
平成 29 年度 第 1 回三重県感染対策 援ネットワーク研修会 2017/07/09 ( 臨床第 2 講義室 ) 講演 2 アンチバイオグラムの活 アンチバイオグラム作り 使い 独 政法 地域医療機能推進機構 四 市 津医療センター 薬剤科 副薬剤科 歳也 Japan Community Health care Organization (JCHO) Yokkaichi Hazu Medical
概要 (2006 年 1 2 3 月分 ) 本サーベイランスは 参加医療機関において血液および髄液から分離された各種細菌の検出状況や薬剤感受性パターンの動 向を把握するとともに 新たな耐性菌の早期検出等を目的とする これらのデータを経時的に解析し臨床の現場に還元することによって 抗菌薬の安全で有効な使用方法や院内感染制御における具体的かつ確実な情報を提供する 検体 2005 年 2006 年 10~12
CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str
cefaclor(ccl),cefuroxime(cxm),cefixime (CFIX),cefteram(CFTM),cefdinir(CFDN) pneumoniae,streptococcus pyogenes Moraxella catarrhalis,haemophilus influenzae,escherichia coli, Klebsiella pneumoniae,proteus
366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486
400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
Table 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and
Genus Corynebacteria Non-lipophilic The nonlipophilic bacteria may be classified as fermentative and non-fermentative: Fermentative Corynebacteria Cor
Corynebacterium kroppenstedtii Genus Corynebacteria Non-lipophilic The nonlipophilic bacteria may be classified as fermentative and non-fermentative: Fermentative Corynebacteria Corynebacterium diphtheriae
252166.indd
BBLCRYSTAL for Windows Ver.5.4 NEISSERIA/HAEMOPHILUS CDC BLOOD AGAR CDC BLOOD AGAR ALTERNATE BLOOD AGAR BBL SCHAEDLER BLOOD AGAR 2007/7 ENTERIC/NON FERMENTER 252166 1. 2 2. 3 3. 4 4. 5 5. 7 6. BBL 8 7.
CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac
CHEMOTHERAPY DEC. 1988 phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepacia 1 Bacteroides bivius Propionibacterium granulosum
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY
日本化学療法学会雑誌第65巻第3号
μ Key words Chlamydia trachomatis C. trachomatis I Table1.Observation items, categories and scores Observation item Category Score Body temperature () Lower abdominal pain Uterine corpus tenderness Condition
CHEMOTHERAPY OCT. 1994 Tazobactam Piperacillin Fig. I. Chemical structures of tazobactam and piperacillin. Table 1. Media used for preculture and MIC determination BHIB: Brain heart infusion broth (Difco),
CHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
THE JAPANESE JOURNAL OF ANTIBIOTICS 63 13 243 ( 37 ) 2007 12 2008 5 19 863 methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof
242 ( 36 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 prulifloxacin * ** ** CMC * ** 2010 2 22 Prulifloxacin ulifloxacin (UFX) 3 1 2003 12 2004 5 19 534 2 2005 12 2006 5 19 805 3 THE JAPANESE JOURNAL OF
Key words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz
VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine
日本化学療法学会雑誌第53巻第S-1号
Doripenem in vitro Doripenem in vitro 7 7 3 DRPM in vitro DRPM 00 DRPM Staphylococcus Streptococcus µ gml MIC90 Moraxella catarrhalishaemophilus influenzae µ gml MIC90 imipenem IPM panipenem meropenemmepm
Title 尿路感染症分離菌の年次的変遷と薬剤感受性の検討 ( ニューキノロン系を中心として ) 深津, 英捷 ; 本多, 靖明 ; 水本, 裕之 ; 瀧, 知弘 ; 三井, Author(s) 々村, 仁志 ; 羽田野, 幸夫 ; 平岩, 親輔 ; 吉川, 和宏 ; 山田彰 ; 瀬川, 昭夫 Ci
Title 尿路感染症分離菌の年次的変遷と薬剤感受性の検討 ( ニューキノロン系を中心として ) 深津, 英捷 ; 本多, 靖明 ; 水本, 裕之 ; 瀧, 知弘 ; 三井, Author(s) 々村, 仁志 ; 羽田野, 幸夫 ; 平岩, 親輔 ; 吉川, 和宏 ; 山田彰 ; 瀬川, 昭夫 Citation 泌尿器科紀要 (1992), 38(11): 1215-1223 Issue Date
VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega
1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity
Fig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);
VOL.35 S-2 CHEMOTHERAPY Fig.1 Chemical structure of carumonam CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical
Fig.1 Chemical structure of BAY o 9867
Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985
VOL.30 NO.10 CHEMOTHERAPY 1123 Fig,1 Group B case 6 hepatolithiasis,e.k.66 y.0.,f.45kg Postoperative wound infection Fig.2 Group B case 15 gastric cancer,k.k.60 y.o.,m. Postoperative peritonitis Fig.3
01-a-”Oı€™JŠY-4.02
Apr. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 105( 1 ) Fosfomycin b- 2004 11 24 fosfomycin (FOM) FOM b- (cefazolin (CEZ), cefotiam (CTM), cefmetazole (CMZ) piperacillin (PIPC)) b - AmpC b- FOM glucose-6-phosphate
Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not det
Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not detected *: time after last administration Table 2. Concentration
CHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection
VOL.36 S-I CHEMOTHERAPY Tabl 1 List of healthy male volunteers
VOL.36 S-I CHEMOTHERAPY Tabl 1 List of healthy male volunteers CHEMOTHERAPY MAY 1988 Table 2 Experimental schedule of CS-807 administration and sampling of feces Table 3 Isolation of aerobic and anaerobic
日本化学療法学会雑誌第58巻第4号
Escherichia coli Enterococcus faecalisstreptococcus agalactiae Klebsiella pneumoniae Staphylococcus epidermidis E. colie. faecalispseudomonas aeruginosa K. pneumoniae S. agalactiae E. coli E. coli μ p
Table 1-1. Criteria for evaluation Table 2. Criteria for bacteriological efficacy Table 1-2. Criteria for evaluation Table 3. Reasons for exclusion and drop-out from evaluation (clinical efficacy) Table
Helicobacter pylori Helicobacter pylori Helkobacter pylori erythromycin (EM) Mueller Hinton broth (Difco) H. pylori Staphylococcus aureus ATCC 29213 Escherichia coli ATCC25922 amoxicillin (AMPC), clarithromycin
VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )
CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative
Table 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,
第65回日本化学療法学会東日本支部総会 抄録
鍵 76 Clostridioides difficile C. difficile 77 γ γ Mycobacterium avium 78 79 Clostridium difficile Treponema pallidum 80 81 82 in vitro in vitro 83 鍵 Treponema pallidum 84 Chlamydia trachomatis Mycoplasma
- 1 -
- 1 - - 1 - ... 1... 2... 4... 5... 9... 11... 14... 16... 20... 21... 22... 23... 23 - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - ( ) - 10 - - 11 - Pseudomonas aeruginosa Escherichia coli Staphylococcus
two compartment model Mueller-Hinton Mueller-Hinton Mueller-Hinton 86 mitomycin C (s4mc), 5-fluorouracil (5-FU), adriamycin 96 97 thymidylate synthetasects), dihydr ine ATP
MIC MIC...
50 mg 10% 2.7.36 2.7.36 2.7.36... 1 1.6... 1 2.6... 3 3.6... 5 3.16... 5 3.26... 12 3.36... 16 4.6... 17 5.6... 19 6.6... 20 2.7.3.3.16-1 MIC... 9 2.7.3.3.16-2 MIC... 10 2.7.3.3.16-3 MIC E. coli... 11
「薬剤耐性菌判定基準」 改定内容
Ver.3.1 Ver.3.2 改訂内容 (2019 年 1 月 ) 改訂対象改訂前改訂後 メチシリン耐性黄色ブドウ球菌 (MRSA) ペニシリン耐性肺炎球菌 (PRSP) 多剤耐性緑膿菌 (MDRP) 多剤耐性アシネトバクター属 (MDRA) 概要 MPIPC が R の Staphylococcus aureus ( または CFX がディスク拡散法で R ) または選択培地で MRSA と確認された菌微量液体希釈法の基準
CHEMOTHERAPY
VOL.40 S-1 coagulase negative Staphylococcus sp, methicillin- resistant Staphylococcus aureus (MRSA), Enterococcus faecalis, Escherichia coli, Citrobacter freundii, Klebsiella pneumoniae, Enterobacter
Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Assoc
J Infect Chemother (2012) 18:609 620 DOI 10.1007/s10156-012-0434-3 SURVEILLANCE Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of
) Meropenem Chemotherapy (Tokyo) ) panipenem/betamipron Chemotherapy (Tokyo) ) Meropenem Chemotherapy (Toky
2.7 2.7.5 1) 199846410-437 2) UTI ( )UTI ( 3 )Chemotherapy (Tokyo) 1986 34408-441 3) () 199745762-778 4) 1992 5) 199543 6) Chemotherapy (Tokyo) 199139687-689 7) Imipenem/Cilastatin sodium (MK-0787/MK-0791)
HPM_442_F_TgCHG_1128
3M TM Chlorhexidine Gluconate IV Securement Dressings Tegaderm TM CHG Support CRBSI Prevention TegadermTM CHG Dressing 2w/w% 60% N. Safdar, Intensive Care Med 2004 30 62-7 Guideline Centers for Disease
pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.
pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P. aeruginosa 30, P. maltophilia pyogenes 32, Escherichia
THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 June 2014 STFX mg mg mg mg mg 1
June 2014 THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 175 29 1 2 2 2 2 2 3 4 4 5 5 2 2 1 2 3 4 5 2014 4 15 STFX 50 mg 10% 2011 8 1 100 mg 1 1 2011 12 2013 5 226 1,186 1,089 1,069 2.11% 23/1,089 1.10% 12/1,089